Print Page

给 医 护 专 业 人 员 的 信
 
Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections (Letter to Healthcare Professionals) (English Only)
 
 
 
附件:
  1. Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections  
Related Information:
Singapore: Imbruvica® (ibrutinib) package insert updates to dose modifications f... 上载于 2022-10-05
European Union: Imbruvica (ibrutinib): new risk minimisation measures, including... 上载于 2022-10-03
Canada: Imbruvica (ibrutinib): Risk of serious and fatal cardiac arrhythmias or ... 上载于 2022-08-30
加拿大：安全审查总结 - Imbruvica (伊布替尼) – 评估严重和危及生命的心律异常(室性快速性心律失常)的潜在风险 上载于 2018-07-27
新加坡：伊布替尼乙肝激活的风险 上载于 2017-12-28
英国：伊布替尼 (Imbruvica▼)：室性快速性心律失常的报告; 乙型肝炎复发及机会感染的风险 上载于 2017-08-16
 
back